As an advanced practice nurse, you will likely experience
patient encounters with complex comorbidities. For example,
consider a female patient who is pregnant who also presents
with hypertension, diabetes, and has a recent tuberculosis
infection. How might the underlying pathophysiology of these
conditions affect the pharmacotherapeutics you might
recommend to help address your patient’s health needs? What
education strategies might you recommend for ensuring positive
patient health outcomes?
For this Discussion, you will be assigned a patient case study
and will consider how to address the patient’s current drug
therapy plans. You will then suggest recommendations on how
to revise these drug therapy plans to ensure effective, safe, and
quality patient care for positive patient health outcomes.
To Prepare
· Review the Resources for this module and reflect on the
different health needs and body systems presented.
· Your Instructor will assign you a complex case study to focus
on for this Discussion.
· Consider how you will practice critical decision making for
prescribing appropriate drugs and treatment to address the
complex patient health needs in the patient case study you
selected.
ASSIGNMENT: Case study has been attached below for this
assignment.

Post
a brief description of your patient’s health needs from the
patient case study you assigned. Be specific. Then, explain the
type of treatment regimen you would recommend for treating
your patient, including the choice or pharmacotherapeutics you
would recommend and explain why. Be sure to justify your
response. Explain a patient education strategy you might
recommend for assisting your patient with the management of
their health needs. Be specific and provide examples.
Required Readings
Rosenthal, L. D., & Burchum, J. R. (2018). Lehne’s
pharmacotherapeutics for advacned practice providers. St.
Louis, MO: Elsevier.
Chapter 44, “Anticoagulant and Antiplatelet Drugs” (pp. 451–
472)
Chapter 45, “Drugs for Deficiency Anemias” (pp. 473–483)
Chapter 48, “Estrogens and Progestins: Basic Pharmacology and
Noncontraceptive Applications” (pp. 521–533)
Chapter 49, “Birth Control” (pp. 535–547)
Chapter 50, “Androgens” (pp. 549–556)
Chapter 51, “Drugs for Erectile Dysfunction and Benign
Prostatic Hyperplasia” (pp. 557–569)
Chapter 68, “Basic Principles of Antimicrobial Therapy” (pp.
769–781)

Chapter 69, “Drugs That Weaken the Bacterial Cell Wall I:
Penicillins” (pp. 783–790)
Chapter 73, “Sulfonamides and Trimethoprim” (pp. 619–826)
Chapter 74, “Drug Therapy of Urinary Tract Infections” (pp.
827–831)
Chapter 75, “Antimycobacterial Agents” (pp. 833–847)
Chapter 76, “Miscellaneous Antibacterial Drugs” (pp. 849–853)
Chapter 77, “Antifungal Agents” (pp. 855–866)
Chapter 78, “Antiviral Agents I: Drugs for Non-HIV Viral
Infections” (pp. 867–886)
Chapter 80, “Drug Therapy of Sexually Transmitted Diseases”
(pp. 905–911)
Lunenfeld, B., Mskhalaya, G., Zitzmann, M., Arver, S.,
Kalinchenko, S., Tishova, Y., & Morgentaler, A. (2015).
Recommendations on the diagnosis, treatment and monitoring of
hypogonadism in men. Aging Male, 18(1), 5–15.
doi:10.3109/13685538.2015.1004049
This article presents recommendations on the diagnosis,
treatment, and monitoring of hypogonadism in men. Reflect on
the concepts presented and consider how this might impact your
role as an advanced practice nurse in treating men’s health
disorders.
Montaner, J. S. G., Lima, V. D., Harrigan, P. R., Lourenço, L.,
Yip, B., Nosyk, B., … Kendall, P. (2014). Expansion of HAART
coverage is associated with sustained decreases in HIV/AIDS

morbidity, mortality and HIV transmission: The “HIV
Treatment as Prevention” experience in a Canadian setting.
PLoS ONE, 9(2), e87872. Retrieved from
https://doi.org/10.1371/journal.pone.0087872
This study examines HAART therapy and its sustainability and
profound population-level decrease in morbidity, mortality, and
HIV transmission.
Roberts, H., & Hickey, M. (2016). Managing the menopause: An
update. Maturitas, 86(2016), 53–58.
.https://doi.org/10.1016/j.maturitas.2016.01.007
This article provides an update on treatments on Vasomotor
symptoms (VMS), genito-urinary syndrome of menopause
(GSM), sleep disturbance, sexual dysfunction, and mood
disturbance that are common during the menopause transition.
Agency for Healthcare Research and Quality. (2014). Guide to
clinical preventive services, 2014: Section 2. Recommendations
for adults. Retrieved from
http://www.ahrq.gov/professionals/clinicians-
providers/guidelines-recommendations/guide/section2.html